Related Experiment Video

Updated: Nov 7, 2025

Generation of a RIP1 Knockout U937 Cell Line Using the CRISPR-Cas9 System
08:15

Generation of a RIP1 Knockout U937 Cell Line Using the CRISPR-Cas9 System

Published on: April 11, 2025

576

Targeting RIP Kinases in Chronic Inflammatory Disease

Mary Speir1,2, Tirta M Djajawi1,2, Stephanie A Conos1,2

  • 1Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, VIC 3168, Australia.

Biomolecules
|April 30, 2021
PubMed

Insights

Receptor-interacting protein (RIP) kinases RIPK1 and RIPK3 drive inflammation through cell death pathways. Dysregulation of these kinases contributes to chronic inflammatory diseases, suggesting RIP kinases as potential therapeutic targets.

Area of Science:

  • Immunology
  • Molecular Biology
  • Cell Biology

Background:

  • Chronic inflammatory disorders involve exaggerated immune cell responses.
  • Extrinsic cell death pathways, including apoptosis and necroptosis, are key drivers of inflammation.
  • Mutations in cell death pathway repressors are linked to autoinflammatory disorders.

Purpose of the Study:

  • To review inflammatory cell death pathways regulated by RIPK1 and RIPK3.
  • To discuss the role of dysregulated RIPK1/RIPK3 signaling in chronic inflammatory conditions.
  • To explore the therapeutic potential of targeting RIP kinases in clinical settings.

Main Methods:

  • Review of scientific literature on RIP kinases, cell death, and inflammation.
  • Analysis of signaling pathways involving RIPK1, RIPK3, TNF, and NLRP3 inflammasome.
  • Examination of evidence linking RIP kinase dysregulation to specific inflammatory disorders.

Main Results:

  • RIPK1 and RIPK3 regulate pro-inflammatory cytokine production and inflammasome activation.
  • Dysregulated RIPK1/RIPK3 signaling contributes to chronic inflammation in joints, skin, and the gastrointestinal tract.
  • Emerging evidence supports targeting RIP kinases for therapeutic intervention.

Conclusions:

  • RIPK1 and RIPK3 are critical regulators of inflammatory cell death.
  • Aberrant RIP kinase signaling is implicated in various chronic inflammatory diseases.
  • Targeting RIP kinases represents a promising strategy for treating inflammatory disorders.
Keywords:
RIP kinasesapoptosischronic inflammatory diseaseinterleukin-1necroptosistumour necrosis factor

More Related Videos

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

557
A Microphysiological System to Study Leukocyte-Endothelial Cell Interaction during Inflammation12:55

A Microphysiological System to Study Leukocyte-Endothelial Cell Interaction during Inflammation

Published on: December 9, 2021

3.5K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.9K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.3K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
15.9K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
304